Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term immunotherapy. Found 25 abstracts

no pagination
Abbosh PH, Plimack ER. Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2018 Jan 20;4(1):9-18.   PMCID: PMC5798524
Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncol. 2018 Jun;14(14):1409-21.
Ghatalia P, Zibelman M, Geynisman DM, Plimack E. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. Therapeutic advances in medical oncology. 2018 Jul;10:1758835918788310.   PMCID: PMC6066800
Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LM, Abu-Akeel M, Liu C, Sauter JL, Rekhtman N, Chang E, Callahan MK, Chaft JE, Voss MH, Tenet M, Li XM, Covello K, Renninger A, Vitazka P, Geese WJ, Borghaei H, Rudin CM, Antonia SJ, Swanton C, Hammerbacher J, Merghoub T, McGranahan N, Snyder A, Wolchok JD. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Apr 12;33(5):843-852 e4.   PMCID: PMC5953836
Marty R, de Prisco N, Carter H, Font-Burgada J. MHC-I genotype drives early immune selection of oncogenic mutations. Molecular & cellular oncology. 2018 Jan;5(2):e1409863.   PMCID: PMC5821412
Winer A, Bodor JN, Borghaei H. Identifying and managing the adverse effects of immune checkpoint blockade. Journal of thoracic disease. 2018 Feb;10(Suppl 3):S480-S489.   PMCID: PMC5861268
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr;123(7):1259-71.   PMCID: PMC5705038
Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Geynisman DM, Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website. Kidney cancer. 2017 Nov 27;1(2):151-9.   PMCID: PMC6179107
Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, de Prisco N, Ideker T, Hildebrand WH, Font-Burgada J, Carter H. MHC-I Genotype Restricts the Oncogenic Mutational Landscape. Cell. 2017 Nov 30;171(6):1272-1283 e15.   PMCID: PMC5711564
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017 Jul;28(7):1436-47.   PMCID: PMC5834038
Jochems C, Hodge JW, Fantini M, Fujii R, Morillon Ii YM, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016 Dec 27;7(52):86359-73.   PMCID: PMC5341330
Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91.
Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy. 2016 Jun;8(7):785-98.
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age. Future Oncol. 2016 Oct;12(19):2227-42.   PMCID: PMC5066115
Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy. 2012 May;61(5):629-41.
Wang SZ, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology Immunotherapy. 2012 Jan;61(1):49-61.   PMCID: PMC3517883
Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU international. 2010 Aug;106(3):357-61.   PMCID: *
Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference. Cancer . 2009 Jan;115(10):2247-51.   PMCID: PMC2892290
Boorjian SA, Berglund RK, Maschino AC, Savage CJ, Herr HW. Fibrin Clot Inhibitor Medication and Efficacy of Bacillus Calmette-Guerin for Bladder Urothelial Cancer. Journal of Urology. 2009 Oct;182(4):1306-11.
Ignatoff JA, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group. Urologic Oncology-Seminars and Original Investigations. 2009 Sep;27(5):496-501.   PMCID: PMC2743955
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term immunotherapy

immunotherapy bladder cancer therapy transitional-cell carcinoma cancer major histocompatibility complex urothelial carcinoma kidney cancer Ctla-4 cancer predisposition antigen presentation lymphoma biomarkers human leukocyte antigen cancer susceptibility prediction neoantigens Immunotherapy urinary-bladder clinical trials expression Pd-1 methods immunology carcinoma Combined Modality Therapy Neoplasm Metastasis randomized trial Dendritic cell Ovarian cancer-Vaccine-Clinical trial-Consolidation therapy manuscript instillation Head and Neck Neoplasms Monoclonal Antibodies risk Neoadjuvant Therapy adverse effects interest organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those anti-cd20 monoclonal-antibody transgenic mice neoadjuvant chemotherapy immunoediting DNA damage response peptide molecular oncology checkpoint blockade Immunologic Factors tumor-associated antigen immune-response Superficial transitional cell carcinoma checkpoint inhibitors oncology-group Urothelial carcinoma Adcc repair Retrospective renal cancer AstraZeneca and Merck directed clinical trial support from Bristol-Myers Squibb cytotoxic T-lymphocyte associated protein 4 Targeted therapy reproductive factors adriamycin head and neck cancer toxicity Mycobacterium bovis lymphocytes prostate cancer phase-i receptor agonists toxicities genitourinary cancer pathology mortality urothelial cell Clinical Trials as Topic Tmb lung cancer chemotherapy high affinity CD16 chemoresponse response criteria etiology genetics neu Treatment Outcome in-situ vascular endothelial growth factor superficial bladder-cancer checkpoint inhibitor survival disclosed No writing assistance was utilized in the production of this waterfall plots The authors have no other relevant affiliations or financial involvement with any AD32 regulatory t-cells Urinary Bladder Neoplasms n-trifluoroacetyladriamycin-14-valerate ad-32 precision medicine Fdg-pet mutation burden NK lysis Intravesical institutionally directed clinical trial support from Horizon Pharma ER Plimack human papillomavirus neoadjuvant programmed death 1 BCG United States cytokine oncogenes National Cancer Institute (US) Transgenic mouse Eli Lilly has served on advisory boards and as consultant for Genentech upper tract urothelial carcinoma diagnosis fibronectin HER2 attachment fc-gamma-ri predictive biomarker Antibody therapy prospective randomized trial analog metastatic breast-cancer Molecular Targeted Therapy implantation Patient Selection Vegf adjuvant Antitumor immunity targeted therapy carcinoma urinary bladder-anticoagulants-urothelium-Mycobacterium bovis management cisplatin overexpression Checkpoint inhibitors Neoplasm Staging Carcinoma in situ therapeutic use maintenance immune checkpoint blockade androgen efficacy Fox Chase Cancer Center renal cell carcinoma immunoediting immunology cetuximab Toll-like receptor 4 agonist her-2 receptor
Last updated on Tuesday, December 04, 2018